Alan Cohen, MD

Dr. Cohen is a vet­er­an in clin­i­cal devel­op­ment for meta­bol­ic and rare dis­eases and a board-cer­ti­fied pul­mo­nolo­gist and pedi­atric subspecialist.

Chief Medical Officer & SVP of Monogenic Diseases

His research and drug devel­op­ment career have includ­ed lead­er­ship posi­tions at both biotech and phar­ma­ceu­ti­cal com­pa­nies, includ­ing BridgeBio/​Eidos Ther­a­peu­tics, Bay­er, Edding­pharm (as CMO), Inter­mune (acquired by Roche/​Genentech), Boehringer Ingel­heim, and Jazz Phar­ma­ceu­ti­cals (as CMO).

He is the author of over 100 peer-reviewed arti­cles, abstracts, plat­form pre­sen­ta­tions, and book chap­ters in his areas of inter­est and exper­tise, includ­ing CF, micro­bi­ol­o­gy, and car­diopul­monary dis­or­ders. He has remained clin­i­cal­ly active in direct patient care for the major­i­ty of his more than 30-year med­ical career, most recent­ly serv­ing as adjunct clin­i­cal and teach­ing fac­ul­ty at Stan­ford Uni­ver­si­ty School of Med­i­cine in the Depart­ment of Pedi­atric Pulmonology.

Dr. Cohen received his MD from New York Med­ical Col­lege, before com­plet­ing his res­i­den­cy and fel­low­ship at the Uni­ver­si­ty of Col­orado / Nation­al Jew­ish Cen­ter for Immunol­o­gy and Res­pi­ra­to­ry Diseases.